Richard M. Toselli - Nov 17, 2022 Form 4 Insider Report for INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV)

Role
CEO and CMO, Director
Signature
/s/ Heather Hamel, Attorney-in-fact
Stock symbol
NVIV
Transactions as of
Nov 17, 2022
Transactions value $
$0
Form type
4
Date filed
11/21/2022, 04:04 PM
Previous filing
Dec 23, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVIV Stock Option (right to buy) Award $0 +61K $0.00 61K Nov 17, 2022 Common Stock 61K $2.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on November 17, 2022. The shares underlying the option vest over two years, with 50% of the shares vesting on November 17, 2023 and the remaining shares vesting on November 17, 2024.